NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that multiple ...
The RedirecTT-1 trial showed a 78.9% response rate for talquetamab and teclistamab in relapsed multiple myeloma with extramedullary disease, significantly improving outcomes. INCA33989, a monoclonal ...
Reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent Phase 1 trials of approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback